These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 8755703)

  • 1. A second dose of MMR vaccine for children in the United Kingdom.
    Commun Dis Rep CDR Wkly; 1996 Jul; 6(30):259. PubMed ID: 8755703
    [No Abstract]   [Full Text] [Related]  

  • 2. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 3. Sentinel surveillance shows small decline in MMR coverage.
    Commun Dis Rep CDR Wkly; 1998 Sep; 8(36):317, 320. PubMed ID: 9782644
    [No Abstract]   [Full Text] [Related]  

  • 4. MMR vaccine coverage at 24 months stabilises in the UK.
    Commun Dis Rep CDR Wkly; 1999 Mar; 9(13):113, 116. PubMed ID: 10230112
    [No Abstract]   [Full Text] [Related]  

  • 5. Moving the second dose of measles-mumps-rubella vaccine to school entry: implications for control of rubella.
    Heath TC; Burgess MA; Forrest JM
    Commun Dis Intell; 1998 Aug; 22(8):157-8. PubMed ID: 9735550
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR.
    Mitchell LA; Tingle AJ; Décarie D; Lajeunesse C
    Can J Public Health; 1998; 89(5):325-8. PubMed ID: 9813922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMR vaccine--one year on.
    Walker D
    Practitioner; 1990 May; 234(1489):550-2. PubMed ID: 2392406
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme.
    Broliden K; Abreu ER; Arneborn M; Böttiger M
    Vaccine; 1998; 16(2-3):323-7. PubMed ID: 9607050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded programme on immunization. Vaccine efficacy in a measles immunization programme.
    Wkly Epidemiol Rec; 1992 Jul; 67(30):224-7. PubMed ID: 1498025
    [No Abstract]   [Full Text] [Related]  

  • 12. Need for measles revaccination.
    John TJ
    Indian Pediatr; 1998 Aug; 35(8):789-91. PubMed ID: 10216577
    [No Abstract]   [Full Text] [Related]  

  • 13. Catch-up immunization programs will eliminate measles threat for most schoolchildren.
    Rafuse J
    CMAJ; 1996 May; 154(10):1567-8. PubMed ID: 8625011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines.
    Miller E; Hill A; Morgan-Capner P; Forsey T; Rush M
    Vaccine; 1995 Jun; 13(9):799-802. PubMed ID: 7483800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles, mumps, and rubella: recommendations for children/adolescents.
    Nurse Pract; 1996 Oct; 21(10):88, 91-2, 94. PubMed ID: 8895194
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12-24 months of age.
    Gatchalian S; Cordero-Yap L; Lu-Fong M; Soriano R; Ludan A; Chitour K; Bock HL
    Southeast Asian J Trop Med Public Health; 1999 Sep; 30(3):511-7. PubMed ID: 10774661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinico-immunologic evaluation of a trivalent vaccine against measles, rubella and mumps].
    Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G
    Minerva Pediatr; 1989 Mar; 41(3):117-22. PubMed ID: 2747598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to measles-mumps-rubella vaccine in children on dialysis.
    Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ
    Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.